Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)

Study identification

• EU PAS number:
  EUPAS1000000619
• Study ID:
  1000000619
• Official title and acronym:
  Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study; identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs,; from the perspective of the Italian administrative healthcare data. Methods: Through cross-linkage of Italian administrative healthcare data 2015-2017 (accrual period) in the ReS database, patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of supplies of CKD-aP-related treatment (according to common clinical practice and guidelines) and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (Servizio Sanitario Nazionale - SSN). ; Results: Among about 5 million inhabitants, 1239 people on hemodialysis for ≥2 years were identified; of them, patients affected by CKD-aP were 218. Patients with CKD-aP (vs non-CKD-aP) were older and with more comorbidities. During the follow-up year, on average, the SSN spent € 37,065 per case, € 31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost. ; Conclusions: This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP.; Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP.; The discovery of appropriate and effective treatments for this condition might offer cost offsets.
• Study status:
  Finalised

Research institutions and networks

Institutions

Fondazione ReS (Ricerca e Salute), CINECA partner

Italy

Study timelines

Date when funding contract was signed

Actual:02/05/2024

Study start date

Actual:03/06/2024

Date of final study report

Actual:03/06/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Funding for this study was provided by an unconditional grant from Vifor Pharma, Glattbrugg, Switzerland. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing and publishing the report.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable